6785 Stock Overview
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Alar Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$320.50 |
| 52 Week High | NT$465.00 |
| 52 Week Low | NT$116.00 |
| Beta | 0.23 |
| 1 Month Change | 3.72% |
| 3 Month Change | 58.66% |
| 1 Year Change | 81.59% |
| 3 Year Change | 493.52% |
| 5 Year Change | n/a |
| Change since IPO | 612.22% |
Recent News & Updates
Shareholder Returns
| 6785 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -9.2% | 2.1% | 1.8% |
| 1Y | 81.6% | 13.1% | 28.5% |
Return vs Industry: 6785 exceeded the TW Pharmaceuticals industry which returned 13.1% over the past year.
Return vs Market: 6785 exceeded the TW Market which returned 28.5% over the past year.
Price Volatility
| 6785 volatility | |
|---|---|
| 6785 Average Weekly Movement | 14.9% |
| Pharmaceuticals Industry Average Movement | 3.9% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 8.2% |
| 10% least volatile stocks in TW Market | 2.0% |
Stable Share Price: 6785's share price has been volatile over the past 3 months.
Volatility Over Time: 6785's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 22 | Yung-Shun Wen | www.alarpharm.com |
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. It is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid use disorder; ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; ALA-4000 which is in pre-clinical stage for treatment of Parkinson’s disease; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.
Alar Pharmaceuticals Inc. Fundamentals Summary
| 6785 fundamental statistics | |
|---|---|
| Market cap | NT$21.41b |
| Earnings (TTM) | NT$382.62m |
| Revenue (TTM) | NT$469.27m |
56.0x
P/E Ratio45.6x
P/S RatioIs 6785 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6785 income statement (TTM) | |
|---|---|
| Revenue | NT$469.27m |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$469.27m |
| Other Expenses | NT$86.66m |
| Earnings | NT$382.62m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.73 |
| Gross Margin | 100.00% |
| Net Profit Margin | 81.53% |
| Debt/Equity Ratio | 0% |
How did 6785 perform over the long term?
See historical performance and comparison